PT2464725T - Produção de proteínas em meios de cultura celular isentos de glutamina - Google Patents

Produção de proteínas em meios de cultura celular isentos de glutamina

Info

Publication number
PT2464725T
PT2464725T PT107450645T PT10745064T PT2464725T PT 2464725 T PT2464725 T PT 2464725T PT 107450645 T PT107450645 T PT 107450645T PT 10745064 T PT10745064 T PT 10745064T PT 2464725 T PT2464725 T PT 2464725T
Authority
PT
Portugal
Prior art keywords
glutamine
proteins
production
cell culture
culture media
Prior art date
Application number
PT107450645T
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42771984&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2464725(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT2464725T publication Critical patent/PT2464725T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
PT107450645T 2009-08-11 2010-08-06 Produção de proteínas em meios de cultura celular isentos de glutamina PT2464725T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23288909P 2009-08-11 2009-08-11

Publications (1)

Publication Number Publication Date
PT2464725T true PT2464725T (pt) 2020-05-21

Family

ID=42771984

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107450645T PT2464725T (pt) 2009-08-11 2010-08-06 Produção de proteínas em meios de cultura celular isentos de glutamina

Country Status (25)

Country Link
US (8) US8512983B2 (pt)
EP (3) EP3760712A1 (pt)
JP (4) JP5930542B2 (pt)
KR (5) KR20180010324A (pt)
CN (2) CN104059955A (pt)
AU (3) AU2010282733B2 (pt)
BR (1) BR112012002974B1 (pt)
CA (1) CA2770690C (pt)
DK (1) DK2464725T3 (pt)
ES (1) ES2793348T3 (pt)
HK (1) HK1202588A1 (pt)
HR (1) HRP20200768T1 (pt)
HU (1) HUE048980T2 (pt)
IL (2) IL264336B2 (pt)
LT (1) LT2464725T (pt)
MX (2) MX2012001742A (pt)
MY (1) MY186219A (pt)
NZ (1) NZ598677A (pt)
PL (1) PL2464725T3 (pt)
PT (1) PT2464725T (pt)
RU (2) RU2017138926A (pt)
SG (3) SG178358A1 (pt)
SI (1) SI2464725T1 (pt)
WO (1) WO2011019619A1 (pt)
ZA (1) ZA201200763B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US8512983B2 (en) 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
WO2011065940A1 (en) * 2009-11-24 2011-06-03 Biogen Idec Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
EP3434691A1 (en) 2010-12-01 2019-01-30 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
IL310968A (en) 2011-07-01 2024-04-01 Amgen Inc Mammalian cell culture
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
AR088383A1 (es) 2011-10-18 2014-05-28 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2869816A4 (en) 2012-07-09 2016-04-20 Coherus Biosciences Inc FORMANTS OF ETANERCEPT HAVING A REDUCTION MARKED IN INVISIBLE PARTICLES IN THE NU
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
PT2895188T (pt) 2012-09-11 2018-02-08 Coherus Biosciences Inc Etanercept dobrado corretamente de pureza elevada e rendimento excelente
RU2518329C1 (ru) * 2012-12-07 2014-06-10 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Способ получения субстанции рекомбинантного эритропоэтина человека и нанокапсулированная форма рекомбинантного эритропоэтина человека с использованием субстанции, полученной указанным способом
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
BR112015022529A2 (pt) * 2013-03-15 2017-07-18 Genentech Inc meios de cultura de células e processos de produção de anticorpo
CN110951670A (zh) 2013-03-15 2020-04-03 豪夫迈·罗氏有限公司 具有抗氧化剂的细胞培养组合物和多肽生产方法
AR096839A1 (es) * 2013-07-06 2016-02-03 Cadila Healthcare Ltd Proceso mejorado para la producción de anticuerpos monoclonales
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
MX2016009848A (es) * 2014-01-29 2017-02-17 Lg Life Sciences Ltd Método de modulación de la galactosilación de proteína recombinante mediante optimización de medio de cultivo.
CA2937965A1 (en) 2014-01-30 2015-08-06 Coherus Biosciences, Inc. Perfusion media
WO2015148515A1 (en) * 2014-03-24 2015-10-01 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
WO2015163783A1 (ru) * 2014-04-25 2015-10-29 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Способ получения субстанции рекомбинантного эритропоэтина человека и нанокапсулированная форма рекомбинантного эритропоэтина человека с использованием субстанции, полученной указанным способом
BR112016030723B8 (pt) * 2014-07-16 2024-02-27 Heartseed Inc Meios de cultura de células, método para indução da morte celular de células-tronco indiferenciadas e métodos para seleção de cardiomiócitos
JP6978938B2 (ja) 2014-11-25 2021-12-08 コーニング インコーポレイテッド 細胞培養培地延長材料及び方法
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
FR3040860B1 (fr) * 2015-09-10 2020-05-15 Universite de Bordeaux Milieu de conservation injectable pour la conservation de cellules du sang placentaire, de la moelle osseuse et du sang peripherique
KR20180073693A (ko) * 2015-11-09 2018-07-02 브리스톨-마이어스 스큅 컴퍼니 Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법
WO2018002036A1 (en) 2016-06-28 2018-01-04 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
KR20180047404A (ko) * 2016-10-31 2018-05-10 삼성바이오에피스 주식회사 세포 배양 배지에서 원치 않는 배양 부산물을 감소시키는 공정
KR101932137B1 (ko) * 2017-01-02 2018-12-24 연세대학교 산학협력단 당화 증강용 조성물 및 당화 증강된 단백질의 제조방법
JP7271097B2 (ja) 2018-07-17 2023-05-11 シャープ株式会社 基地局装置、端末装置、および、通信方法
US11568955B2 (en) 2018-08-21 2023-01-31 Lonza Ltd Process for creating reference data for predicting concentrations of quality attributes
RU2728377C2 (ru) * 2018-12-28 2020-07-29 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Композиция на основе янтарной кислоты и аспарагина для повышения продуктивности клеточных линий-продуцентов рекомбинантных белков
CN109628378B (zh) * 2019-01-25 2020-07-17 江苏丰华生物制药有限公司 一种利用花生蛋白酶解物培养cho细胞的方法
US10961500B1 (en) 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049494A (en) * 1975-09-04 1977-09-20 The United States Of America As Represented By The Secretary Of Agriculture Vaccine production process
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5185259A (en) 1982-05-05 1993-02-09 Genentech, Inc. Truncated human tissue plasminogen activator
US4853330A (en) 1983-04-07 1989-08-01 Genentech, Inc. Human tissue plasminogen activator
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU572108B2 (en) 1983-01-19 1988-05-05 Genentech Inc. Human tpa production using vectors coding for dhfr protein
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
FR2539642B1 (fr) 1983-01-20 1985-12-13 Choquenet Sa L Filtre-presse comprenant des moyens d'extraction des boues
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5169770A (en) 1987-12-21 1992-12-08 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
ATE113846T1 (de) 1988-06-21 1994-11-15 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
GB2237288A (en) * 1989-10-18 1991-05-01 Celltech Ltd Amplification of a heterologous gene in recombinant eukaryotic host cells
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2074363C (en) 1990-01-22 2004-11-09 David Thomas Vistica Co2-independent growth medium for maintenance and propagation of cells
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2296839T3 (es) 1991-08-14 2008-05-01 Genentech Inc. Variantes de inmunoglobulinas para receptores fc-epsilon especificos.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ATE157455T1 (de) 1993-12-10 1997-09-15 Genentech Inc Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika
AUPM305393A0 (en) 1993-12-20 1994-01-20 Initiating Explosives Systems Proprietary Limited Signal tube of improved oil resistance
AP660A (en) 1994-01-18 1998-08-18 Genentech Inc A method of treatment of parasitic infection using IgE antagonists.
CA2181787A1 (en) 1994-03-03 1995-09-08 Claire M. Doerschuk Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9506249D0 (en) 1995-03-27 1995-05-17 Karobio Ab Media for insect cell cultures
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
PT877626E (pt) 1996-01-23 2003-01-31 Univ Vermont And State Agric C Anticorpos anti-cd1s para utilizacao contra icto
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
EP1516629B1 (en) 1996-11-27 2013-04-03 Genentech, Inc. Humanized anti CD-11a antibodies
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
PT1860187E (pt) 1997-05-15 2011-10-04 Genentech Inc Receptor apo-2
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2190087T3 (es) 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
AU2112199A (en) * 1998-01-12 1999-07-26 Betagene, Inc. Recombinant cell lines for drug screening
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
CN101695574A (zh) 1998-08-11 2010-04-21 拜奥根Idec公司 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
CN1679934B (zh) 1998-11-09 2012-09-05 生物基因Idec公司 使用抗cd20嵌合抗体治疗循环肿瘤细胞相关的血液恶性肿瘤
KR20010099788A (ko) 1998-11-09 2001-11-09 케네쓰 제이. 울코트 Ｂｍｔ 또는 ｐｂｓｃ 이식을 받은 환자의 키메라항-ｃｄ２０ 항체 치료법
JP2003512019A (ja) 1999-01-15 2003-04-02 ジェネンテック・インコーポレーテッド 変化したエフェクター機能を有するポリペプチド変異体
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6383276B1 (en) 1999-03-12 2002-05-07 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
US6506598B1 (en) 1999-04-26 2003-01-14 Genentech, Inc. Cell culture process
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
CA2727172A1 (en) 1999-05-26 2001-01-04 Genentech, Inc. Methods of treatment using anti-erbb antibody-maytansinoid conjugates
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
DE19930748C2 (de) 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
EP1216056A1 (en) 1999-07-12 2002-06-26 Genentech Inc. Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
CN100389825C (zh) 1999-08-11 2008-05-28 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
AU6929100A (en) 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
CA2387108A1 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
WO2002004021A1 (en) 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020009427A1 (en) 2000-03-24 2002-01-24 Wolin Maurice J. Methods of therapy for non-hodgkin's lymphoma
US20030185796A1 (en) 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
CN1441677A (zh) 2000-03-31 2003-09-10 Idec药物公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
AU2001259142C1 (en) 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
WO2001097858A2 (en) 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
JP2003535907A (ja) 2000-06-22 2003-12-02 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
CN1592645A (zh) 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
CA2436092A1 (en) 2001-01-29 2002-08-08 Idec Pharmaceutical Corporation Modified antibodies and methods of use
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
CA2438148A1 (en) * 2001-02-15 2002-08-29 Centocor, Inc. Chemically defined medium for cultured mammalian cells
CA2442801A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
EP2359849A1 (en) 2001-04-02 2011-08-24 Genentech, Inc. Combination therapy
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
WO2002101019A2 (en) 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
JP2005515161A (ja) 2001-06-14 2005-05-26 インターミューン インコーポレイテッド γ−インターフェロンおよびＢ細胞特異的抗体の併用療法
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
EA200601861A1 (ru) * 2001-08-03 2007-02-27 Дженентек, Инк. ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ
ATE443259T1 (de) 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
EP2348043A1 (en) 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US6852680B2 (en) 2001-10-26 2005-02-08 Ethyl Corporation Dithiocarbamates containing alkylthio and hydroxy substituents
WO2003049694A2 (en) 2001-12-07 2003-06-19 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP2295468B1 (en) 2002-02-14 2015-07-08 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20030219818A1 (en) 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005065348A2 (en) 2003-12-31 2005-07-21 Kalobios, Inc. Transactivation system for mammalian cells
WO2005083058A1 (en) * 2004-03-01 2005-09-09 Ares Trading S.A. Use of a serum-free cell culture medium for the production of il-18bp in mammalian cells
CN100537751C (zh) * 2004-05-12 2009-09-09 华东理工大学 一种适合中国仓鼠卵巢细胞培养的无血清培养基
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
DE102005046225B4 (de) 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
US8994879B2 (en) 2005-10-21 2015-03-31 Thomson Licensing Method and apparatus for audio and video synchronization timestamp rollover correction
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
US20100166741A1 (en) 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
WO2008033517A2 (en) 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
WO2008141207A1 (en) * 2007-05-11 2008-11-20 Amgen Inc. Improved feed media
US20090053786A1 (en) 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides
MX338036B (es) 2007-10-12 2016-03-31 Hoffmann La Roche Expresion proteinica a partir de acidos nucleicos multiples.
CN101226138B (zh) * 2008-02-04 2010-06-09 杭州华锦药业有限公司 一种促肝细胞生长素活性检测方法
US8512983B2 (en) * 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
BR112015022529A2 (pt) 2013-03-15 2017-07-18 Genentech Inc meios de cultura de células e processos de produção de anticorpo
JP5731726B1 (ja) 2014-06-26 2015-06-10 楽天株式会社 情報処理装置、情報処理方法及び情報処理プログラム

Also Published As

Publication number Publication date
US20160024217A1 (en) 2016-01-28
IL264336B2 (en) 2024-02-01
JP2020078307A (ja) 2020-05-28
EP3760712A1 (en) 2021-01-06
CN104059955A (zh) 2014-09-24
JP2013501522A (ja) 2013-01-17
US8512983B2 (en) 2013-08-20
US20170283505A1 (en) 2017-10-05
US20210324098A1 (en) 2021-10-21
RU2017138926A3 (pt) 2021-03-11
IL264336A (en) 2019-02-28
MY186219A (en) 2021-06-30
AU2016238859A1 (en) 2016-10-27
US20190023800A1 (en) 2019-01-24
KR20180010324A (ko) 2018-01-30
LT2464725T (lt) 2020-06-10
WO2011019619A1 (en) 2011-02-17
EP2464725A1 (en) 2012-06-20
CA2770690C (en) 2021-03-09
EP3431588A1 (en) 2019-01-23
JP2018134079A (ja) 2018-08-30
KR101822205B1 (ko) 2018-01-25
US20140024078A1 (en) 2014-01-23
EP2464725B1 (en) 2020-03-25
DK2464725T3 (da) 2020-06-02
RU2012108843A (ru) 2013-09-20
JP6411324B2 (ja) 2018-10-24
ZA201200763B (en) 2013-07-31
AU2010282733B2 (en) 2016-07-14
BR112012002974B1 (pt) 2022-06-07
KR20180114966A (ko) 2018-10-19
SG10201901417UA (en) 2019-03-28
KR20200111282A (ko) 2020-09-28
US20180148510A1 (en) 2018-05-31
AU2016238859B2 (en) 2018-12-13
KR20120088667A (ko) 2012-08-08
HRP20200768T1 (hr) 2020-07-24
MX355650B (es) 2018-04-26
CA2770690A1 (en) 2011-02-17
RU2639288C2 (ru) 2017-12-20
ES2793348T3 (es) 2020-11-13
SG178358A1 (en) 2012-03-29
BR112012002974A2 (pt) 2015-09-01
HK1202588A1 (en) 2015-10-02
US20110091936A1 (en) 2011-04-21
AU2019201603A1 (en) 2019-04-04
JP2016116521A (ja) 2016-06-30
US10982003B2 (en) 2021-04-20
AU2010282733A1 (en) 2012-03-01
HUE048980T2 (hu) 2020-08-28
SG10201500822XA (en) 2015-04-29
KR20180105258A (ko) 2018-09-27
PL2464725T3 (pl) 2020-07-13
MX2012001742A (es) 2012-03-21
US9714293B2 (en) 2017-07-25
JP5930542B2 (ja) 2016-06-08
IL264336B1 (en) 2023-10-01
US20190263921A1 (en) 2019-08-29
SI2464725T1 (sl) 2020-07-31
NZ598677A (en) 2014-06-27
RU2017138926A (ru) 2019-02-11
CN102498206A (zh) 2012-06-13
IL217752A0 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
IL264336A (en) Production of proteins in cell culture medium without glutamine
IL288185A (en) New methods and mediums for growing pluripotent stem cells
EP2398896A4 (en) CELL CULTURE MEDIUM CONTAINING COMBINATIONS OF PROTEINS
HRP20182165T1 (hr) Postupak proizvodnje polipeptida ili virusa od interesa u kontinuiranoj staničnoj kulturi
HK1171790A1 (zh) 用於 蛋白表達的細胞培養基
IL214818A0 (en) Differentiation of pluripotent cells
EP2440652A4 (en) METHOD FOR CULTIVATING STEM CELLS AND PRECURSOR CELLS
IL207402A (en) Units for fermentation and process for making recombinant proteins
EP2519636B8 (en) Production of hemagglutinin-neuraminidase protein in microalgae
GB0808373D0 (en) Scalable cell culture bioreactor and cell culture process
EP2194126A4 (en) PROCESS FOR CONSTRUCTING CELLS WITH HIGH PRODUCTIVITY OF FOREIGN PROTEIN
EP2491111A4 (en) CELL CULTURE HANDLING PRODUCT AND MANUFACTURING AND USE METHOD THEREFOR
PL2480655T3 (pl) Podłoże do hodowli komórkowych
AU2009901852A0 (en) Media and methods for cell culture
GB0919424D0 (en) Improved media for the in vitro culture of mycobacteria
GB0919563D0 (en) Improved media for the in vitro culture of mycobacteria
GB0919581D0 (en) Improved media for the in vitro culture of mycobacteria
AU2010901922A0 (en) Media and methods for cell culture
GB201007863D0 (en) Bioreactor for cell culture
GB0915268D0 (en) Cell culture
GB0922428D0 (en) Cell culture
GB0810304D0 (en) Stem cell culture media and methods